BioCentury
ARTICLE | Emerging Company Profile

Walden: targeting podocytes as linchpin for kidney function

Backed by Arch and UCB, Walden to enter the clinic next year with a mAb and small molecule targeting podocytes for kidney diseases

October 29, 2021 2:03 AM UTC

Launched in October with $51 million in an Arch- and UCB Ventures-led series A, Walden aims to test its theory that targeting podocytes can make diseased kidney tissue healthy again. Walden ...



Access this Article